BridgeBio Total Assets from 2010 to 2025
| BBIO Stock | USD 32.97 0.66 2.04% |
Total Assets | First Reported 2018-12-31 | Previous Quarter 665 M | Current Value 919.3 M | Quarterly Volatility 203.6 M |
Check BridgeBio Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BridgeBio Pharma's main balance sheet or income statement drivers, such as Interest Income of 18.1 M, Depreciation And Amortization of 6.4 M or Interest Expense of 104.3 M, as well as many indicators such as Price To Sales Ratio of 21.86, Dividend Yield of 4.0E-4 or Days Sales Outstanding of 7.38. BridgeBio financial statements analysis is a perfect complement when working with BridgeBio Pharma Valuation or Volatility modules.
BridgeBio | Total Assets |
Latest BridgeBio Pharma's Total Assets Growth Pattern
Below is the plot of the Total Assets of BridgeBio Pharma over the last few years. Total assets refers to the total amount of BridgeBio Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in BridgeBio Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. BridgeBio Pharma's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BridgeBio Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 919.34 M | 10 Years Trend |
|
Total Assets |
| Timeline |
BridgeBio Total Assets Regression Statistics
| Arithmetic Mean | 398,348,639 | |
| Geometric Mean | 257,960,058 | |
| Coefficient Of Variation | 83.97 | |
| Mean Deviation | 300,304,639 | |
| Median | 464,941,000 | |
| Standard Deviation | 334,511,821 | |
| Sample Variance | 111898.2T | |
| Range | 914.7M | |
| R-Value | 0.85 | |
| Mean Square Error | 33429.8T | |
| R-Squared | 0.72 | |
| Significance | 0.000032 | |
| Slope | 59,667,099 | |
| Total Sum of Squares | 1678472.4T |
BridgeBio Total Assets History
Other Fundumenentals of BridgeBio Pharma
BridgeBio Pharma Total Assets component correlations
Click cells to compare fundamentals
About BridgeBio Pharma Financial Statements
BridgeBio Pharma investors utilize fundamental indicators, such as Total Assets, to predict how BridgeBio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 919.3 M | 687.5 M | |
| Intangibles To Total Assets | 0.03 | 0.05 |
Check out the analysis of BridgeBio Pharma Correlation against competitors. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share | Quarterly Revenue Growth 2.371 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.